floxibac 100 mg/ml solution for injection for cattle and pigs
chanelle pharmaceuticals manufacturing limited - enrofloxacin - solution for injection - 100 milligram(s)/millilitre - enrofloxacin - bovine, porcine - antibacterial
floxibac 100 mg/ml solution for injection for cattle and pigs
chanelle pharmaceuticals manufacturing limited - enrofloxacin - solution for injection - 100 mg/ml - enrofloxacin - bovine, porcine - antibacterial
floxibac 100 mg/ml solution for injection for cattle and pigs
chanelle pharmaceuticals manufacturing ltd - enrofloxacin -
floxibac 50 mg/ml solution for injection for cattle, pigs, dogs and cats
chanelle pharmaceuticals manufacturing limited - enrofloxacin - solution for injection - 50 milligram(s)/millilitre - enrofloxacin - bovine, canine, feline, porcine - antibacterial
floxibac 50 mg/ml solution for injection for cattle, pigs, dogs and cats
chanelle pharmaceuticals manufacturing limited - enrofloxacin - solution for injection - 50 mg/ml - enrofloxacin - bovine, canine, feline, porcine - antibacterial
floxibac 50 mg/ml solution for injection for cattle, pigs, dogs and cats
chanelle pharmaceuticals manufacturing ltd - enrofloxacin -
ofloxibact 10 oz
unisearch hc. - ofloxacin,ornidazole - oz - 250,500;mg - 10
ofloxibact 10 tab
unisearch hc. - ofloxacin - tab - 200mg - 10
avelox iv 400 moxifloxacin 400 mg/250 ml (as hydrochloride) intravenous infusion solution bottle
bayer australia ltd - moxifloxacin, quantity: 1.6 mg/ml (equivalent: moxifloxacin hydrochloride, qty 1.744 mg/ml) - injection, intravenous infusion - excipient ingredients: hydrochloric acid; sodium chloride; water for injections; sodium hydroxide - avelox (moxifloxacin hydrochloride) tablets are indicated for the treatment of adults with infections caused by susceptible organisms in the conditions. acute bacterial sinusitis, community acquired pneumonia, acute exacerbations of chronic bronchitis. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions. community acquired pneumonia (caused by susceptible organisms). acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents. (especially penicillin allergy), and when caused by organisms known to be susceptible
avelox iv 400 moxifloxacin 400 mg/250 ml (as hydrochloride) intravenous infusion solution bag
bayer australia ltd - moxifloxacin, quantity: 1.6 mg/ml (equivalent: moxifloxacin hydrochloride, qty 1.744 mg/ml) - injection, intravenous infusion - excipient ingredients: water for injections; sodium chloride; sodium hydroxide; hydrochloric acid - avelox (moxifloxacin hydrochloride) tablets are indicated for the treatment of adults with infections caused by susceptible organisms in the conditions. acute bacterial sinusitis, community acquired pneumonia, acute exacerbations of chronic bronchitis. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions. community acquired pneumonia (caused by susceptible organisms). acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents. (especially penicillin allergy), and when caused by organisms known to be susceptible